首页 Iovance Biotherapeutics, Inc.(usIOVA)-基本信息

Iovance Biotherapeutics, Inc.(usIOVA)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:30.0

最高价:30.0

成交量:1777127.0

昨收价:30.19

最低价:28.77

最新价:29.41

行情图标
概要信息

英文名称:Iovance Biotherapeutics, Inc.


简介:Iovance Biotherapeutics, Inc. 是一家新兴的生物技术公司,专注于培养细胞,使用自体肿瘤浸润淋巴细胞(TIL)治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化


电话:1-650-2607120


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Iovance Biotherapeutics专注于基于肿瘤浸润淋巴细胞(TIL)的新型癌症免疫疗法的开发和商业化。这种方法也称为过继性T细胞疗法,最初由Steven A. Rosenberg博士在国家癌症研究所(National Cancer Institute,NCI)开发。在NCI进行的 II 期临床试验中,NCI报告了使用该技术治疗的患者中有56%和24%分别达到了客观和完整的反应标准。Iovance Biotherapeutics的主要候选产品——lifileucel是一种自体的,即可注入的细胞疗法,在转移性黑色素瘤的治疗中具有独特的疗效。lifileucel是一种过继性T细胞疗法,正在使用肿瘤浸润淋巴细胞(TIL)进行 II 期临床试验,TIL是源自患者肿瘤的T细胞,用于治疗转移性黑素瘤。此外,Iovance Biotherapeutics还在开发LN-145,一种治疗颈部和头颈部癌症的自体过继细胞疗法。除了转移性黑色素瘤,头颈癌和宫颈癌,Iovance Biotherapeutics的TIL治疗技术可能适用于许多其他肿瘤类型,包括卵巢癌,乳腺癌,膀胱癌,结肠直肠癌和其他癌症。公司的目标是将TIL疗法建立为革命性的、易得的主流癌症疗法。Iovance Biotherapeutics公司与Moffitt签订了研究合作和临床补助协议,在一项临床试验中评估TIL治疗,该试验将TIL与nivolumab结合在NSCLC中;与M.D. Anderson癌症中心(M.D. Anderson Cancer Center)达成战略联盟协议,开展临床和临床前研究;与罗斯威尔公园癌症研究所(Roswell Park Cancer Institute)达成战略联盟协议,开展TIL治疗膀胱癌的临床研究;与MedImmune签署有合作协议,开展免疫肿瘤学临床和临床前研究;与俄亥俄州立大学有临床前研究合作;以及与Cellectis S.A.的临床前研究合作,研究转录激活因子样效应核酸酶。

交易日期 交易人 职位 类型 交易份额 价格
2016-08-21 Hillsberg (Sanford J) Director Sell 54000 9.11
2016-05-31 Fardis Maria Chief Executive Officer Buy 550000 --
2015-09-29 Bender (James G) Officer Sell 11274 5.76
2015-09-07 Hillsberg (Sanford J) Director Sell 16500 7.13
2015-09-03 Hillsberg (Sanford J) Director Sell 16000 6.84

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Citadel Advisors Llc 1938868 1.57% -2488645 -56.21% 2019-03-31
Farallon Capital Management, L.L.C. 5725000 4.64% -- -- 2019-03-31
Vanguard Group Inc 5802878 4.70% 23809 0.41% 2019-03-31
BlackRock Fund Advisors 5918142 4.78% 47923 0.82% 2019-07-31
Franklin Resources Inc 8284899 6.71% 1435 0.02% 2019-03-31
Franklin Advisers, Inc. 8225899 6.66% 1435 0.02% 2019-03-31
BlackRock Inc 8835527 7.15% 55336 0.63% 2019-03-31
venBio Select Advisor LLC 10530862 8.53% 269823 2.63% 2019-03-31
Perceptive Advisors LLC 12235811 9.91% -5300 -0.04% 2019-03-31
Great Point Partners LLC 5567348 4.51% -- -- 2019-03-31
Orbimed Advisors, LLC 5548326 4.49% -- -- 2019-03-31
Broadfin Capital, LLC 4328303 3.50% -1622850 -27.27% 2019-03-31
Bank of America Corporation 2081839 1.69% 804804 63.02% 2019-03-31
Northern Trust Investments Inc 2139458 1.73% 15745 0.74% 2019-07-31
FRAZIER MANAGEMENT LLC 2188331 1.77% -- -- 2019-03-31
RA Capital Management, LLC 2610510 2.11% -109942 -4.04% 2019-03-31
Longwood Capital Partners LLC 2944201 2.38% -75000 -2.48% 2019-03-31
Vanguard Investments Australia Ltd 3170425 2.56% 3869 0.12% 2019-07-31
T. Rowe Price Associates, Inc. 3492734 2.83% 187707 5.68% 2019-03-31
State Street Corporation 4063235 3.29% -416017 -9.29% 2019-03-31
Victory Capital Management Inc. 3021927 2.45% 591270 24.33% 2018-12-31
BlackRock Asset Management Canada Ltd 2526619 2.05% 951 0.04% 2019-05-31
Geode Capital Management, LLC 2689404 2.18% 1810920 206.14% 2018-12-31
SSGA Funds Management Inc 2094071 1.70% 6713 0.32% 2019-04-30
Credit Suisse First Boston (CSFB) 1560825 1.27% 529511 51.34% 2018-09-30
BlackRock Institutional Trust Company NA 2133870 1.73% 211640 11.01% 2018-06-30
FMR Inc 1524100 1.24% -369646 -19.52% 2018-09-30
Fidelity SelectCo, LLC 1345034 1.09% -144916 -9.73% 2018-11-30
Fidelity Management and Research Company 1524100 1.24% -369646 -19.52% 2018-09-30
Consonance Capital Management LP 3206073 2.60% 2973677 1279.57% 2018-03-31
Fidelity Management & Research Company 1765947 1.43% 53519 3.13% 2018-10-31
Franklin Advisers Inc 5271235 5.68% -1228 -0.02% 2018-06-30
State Street Corp 3855144 4.16% 1652863 75.05% 2018-06-30
RS Investment Management Co. LLC 1394197 1.50% 55920 4.18% 2018-06-30
Northern Trust Investments N A 1024801 1.11% 152816 17.53% 2018-06-30
Marshall Wace North America LP 1678971 1.87% 1678971 -- 2018-03-31
Qvt Financial LP 1411695 1.49% 287400 25.56% 2018-03-31
J.P. Morgan Investment Management Inc 1188744 1.62% -512056 -30.11% 2017-12-31
Rhenman Partners Asset Management AB 944185 1.29% 233022 32.77% 2017-12-31
AXA Investment Managers UK Ltd 416992 0.46% -251983 -37.67% 2018-01-31
Millennium Management LLC 649651 0.89% -1431829 -68.79% 2017-12-31
AllianceBernstein LP 669587 0.93% -9180 -1.35% 2017-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Russell Small Cap 500373 0.40% 55400 12.45% 2019-07-31
Vanguard Total Stock Market Index Fund 3145206 2.54% 239 0.01% 2019-06-30
T. Rowe Price Health Sciences Fund 2588816 2.09% 793000 44.16% 2019-06-30
iShares Russell 2000 ETF 2520460 2.04% 23450 0.94% 2019-07-30
T. Rowe Price New Horizons Fund 2411886 1.95% 1314900 119.86% 2019-06-30
Franklin Biotechnology Discovery Fund 1990500 1.61% -112300 -5.34% 2019-06-30
Vanguard Extended Market Index Fund 1702054 1.37% -8610 -0.50% 2019-06-30
Franklin Small Cap Growth Fund 1612500 1.30% -636400 -28.30% 2019-06-30
Vanguard Small Cap Index 1415892 1.14% 1415892 -- 2019-06-30
iShares Nasdaq Biotechnology ETF 1219282 0.98% 13496 1.12% 2019-07-30
Victory RS Small Cap Growth Fund 1104045 0.89% -97430 -8.11% 2019-06-30
Fidelity 599602 0.48% -- -- 2019-06-30
Artisan Small Cap Fund 632438 0.51% 632438 -- 2019-06-30
ARK Genomic Revolution ETF 807688 0.65% -18630 -2.25% 2019-06-30
Rhenman Healthcare Eq L/S 849600 0.69% -30000 -3.41% 2019-04-30
Vanguard Small Cap Value Index Fund 881183 0.71% 881183 -- 2019-06-30
iShares Russell 2000 Growth ETF 1051601 0.85% 12264 1.18% 2019-07-30
SPDR 1098926 0.89% 17040 1.58% 2019-07-31
Wells Fargo Small Co Gr Port 497661 0.40% -24878 -4.76% 2019-06-30
Fidelity Special Situations Fund 722803 0.59% 716339 11081.98% 2018-09-30
Fidelity Global Innovators Cl 515655 0.42% 511178 11417.87% 2018-09-30
Wells Fargo Small Company Growth Fund 514246 0.42% -88221 -14.64% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 2152259 1.74% -3609 -0.17% 2019-05-30
ARK Genomic Revolution Multi-Sector ETF 757734 0.61% 66240 9.58% 2019-04-30
TIAA-CREF Quant Small-Cap Equity Fund 450800 0.37% -- -- 2019-02-28
NT R2000 Growth Index Fund - Non-Lending 461720 0.37% 6899 1.52% 2019-03-31
State Street Russell Small/Mid Cap 465703 0.38% 23500 5.31% 2019-03-31
Schwab US Small-Cap ETF 353399 0.29% -- -- 2019-03-29
Rs Investments Custom Growth 349880 0.28% 37450 11.99% 2018-12-31
JNL Multi-Manager Small Cap Growth Fund 349880 0.28% 37450 11.99% 2018-12-31
iShares Russell 2000 Value ETF 784300 0.64% -1293 -0.16% 2018-06-21
MEDICAL BioHealth 284154 0.23% 88000 44.86% 2018-11-30
Vanguard Health Care Index Fund 270947 0.22% 5618 2.12% 2019-01-31
Eventide Healthcare & Life Sciences Fund 280000 0.23% -- -- 2018-09-30
C WorldWide Medical Small & Mid Cap 342528 0.28% -24146 -6.59% 2018-11-30
Fidelity Special Situations Class 722803 0.59% 716339 11081.98% 2018-09-30
Allianz Biotechnologie 330360 0.27% 72690 28.21% 2018-09-30
iShares Nasdaq Biotechnology 1019555 0.79% -1941 -0.19% 2018-09-12
Vanguard Extended Market Idx Inv 986056 1.03% -- -- 2018-07-31
RS Small Cap Growth A 1241765 1.34% 78500 6.75% 2018-06-30
Franklin Small Cap Growth A 1384500 1.45% -- -- 2018-07-31
Franklin Biotechnology Discovery A 1462500 1.53% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 2050267 2.14% -- -- 2018-07-31
iShares Russell 2000 Growth 793491 0.61% -765 -0.10% 2018-09-12
CREF Stock R1 484953 0.51% -72079 -12.94% 2018-07-31
Fidelity Spartan 337210 0.35% -- -- 2018-07-31
TIAA-CREF Small-Cap Equity Instl 299100 0.31% -- -- 2018-07-31
JNL Multi-Manager Small Cap Growth B 296470 0.32% 6700 2.31% 2018-06-30
JPMorgan Small Cap Value A 263100 0.28% -8000 -2.95% 2018-07-31
Eventide Healthcare & Life Sciences A 280000 0.30% 280000 -- 2018-06-30
AST Small Cap Growth Opportunities 224911 0.24% -570 -0.25% 2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 200864 0.21% -563 -0.28% 2018-07-31
Fidelity Advisor 164014 0.17% -145132 -46.95% 2018-07-31
PowerShares DWA Healthcare Momentum ETF 176317 0.17% -- -- 2018-06-28
iShares Micro-Cap 205338 0.21% -- -- 2018-06-21
iShares Russell 2000 Value 784300 0.79% -1293 -0.16% 2018-06-21
Vanguard Instl Ttl Stk Mkt Idx InstlPls 121289 0.14% -- -- 2018-02-28
Met Invt Ser JPMorgan Small Cap Val A 219687 0.30% -84113 -27.69% 2017-12-31
TIAA-CREF International Eq Idx Instl 168900 0.55% 168900 -- 2017-12-31
VALIC Company II Small Cap Value 181900 0.25% -- -- 2017-11-30
State Street Russell Small/Mid Cap Idx Fd Cl I 192703 0.31% 192703 -- 2017-06-30

Timothy E. Morris Timothy E. Morris founded Mvhs Theatre Friends, Inc. Currently, Mr. Morris is Secretary, Chief Financial & Accounting Officer at Iovance Biotherapeutics, Inc. He is also on the board of Humanigen, Inc. and PAION, Inc. In the past Mr. Morris held the position of CFO & Head-Business Development at AcelRx Pharmaceuticals, Inc., SVP-Finance & Global Corporate Development at VIVUS, Inc., Chief Financial Officer of InterPro, Inc., CFO, Vice President-Finance & Administration at RiboGene, Inc., Chief Financial & Accounting Officer at Glycomed, Inc., Chief Financial Officer at Utility.com, CFO, SVP-Finance & Administration at Questcor Pharmaceuticals, Inc., Senior Manager at Ernst & Young LLP and Director at Mvhs Theatre Friends, Inc. Mr. Morris received an undergraduate degree from California State University-Chico.
Merrill A. McPeak Mr. Merrill A. McPeak is an Independent Director at Iovance Biotherapeutics, Inc., an Independent Director at Research Solutions, Inc., a President at McPeak & Associates and a Member at Council on Foreign Relations, Inc. He is on the Board of Directors at Iovance Biotherapeutics, Inc., Research Solutions, Inc., FoundationWorks, Inc. and Saab Sensis Corp. Mr. McPeak was previously employed as an Independent Director by Lilis Energy, Inc., an Independent Director by Aerojet Rocketdyne Holdings, Inc., a Chairman by Mosquito Consolidated Gold Mines Ltd., a Lead Independent Director by Miller Energy Resources, Inc., a Chairman by American Battle Monuments Commission (Virginia), a Chairman by Coast Plating, Inc., a Vice Chairman by QPC Lasers, Inc., an Independent Director by DGT Holdings Corp., a Chairman by EthicsPoint, Inc., a Chairman by ECC International Corp. (Florida), a Member by United States Joint Chiefs of Staff, a Chief of Staff by United States Air Force, and a Principal by Rubicon Global Halal Advisors LLC. He also served on the board at Point Blank Solutions, Inc., Quintessence Photonics Corp., MathStar, Inc., Health Sciences Group, Inc., Gigabeam Corp., Brilliant Light Power, Inc., Western Power & Equipment Corp., Trans World Airlines, Inc., Praegitzer Industries, Inc., TWA Corp., Suvanza, Raven Acquisition Corp., Global Compliance Services, Inc., NAVEX Global, Inc., Rocketplane Global, Inc. and Valence Surface Technologies LLC. He received his undergraduate degree from San Diego State University, an undergraduate degree from The National War College and a graduate degree from George Washington University.
Merrill A. McPeak Mr. Merrill A. McPeak is an Independent Director at Iovance Biotherapeutics, Inc., an Independent Director at Research Solutions, Inc., a President at McPeak & Associates and a Member at Council on Foreign Relations, Inc. He is on the Board of Directors at Iovance Biotherapeutics, Inc., Research Solutions, Inc., FoundationWorks, Inc. and Saab Sensis Corp. Mr. McPeak was previously employed as an Independent Director by Lilis Energy, Inc., an Independent Director by Aerojet Rocketdyne Holdings, Inc., a Chairman by Mosquito Consolidated Gold Mines Ltd., a Lead Independent Director by Miller Energy Resources, Inc., a Chairman by American Battle Monuments Commission (Virginia), a Chairman by Coast Plating, Inc., a Vice Chairman by QPC Lasers, Inc., an Independent Director by DGT Holdings Corp., a Chairman by EthicsPoint, Inc., a Chairman by ECC International Corp. (Florida), a Member by United States Joint Chiefs of Staff, a Chief of Staff by United States Air Force, and a Principal by Rubicon Global Halal Advisors LLC. He also served on the board at Point Blank Solutions, Inc., Quintessence Photonics Corp., MathStar, Inc., Health Sciences Group, Inc., Gigabeam Corp., Brilliant Light Power, Inc., Western Power & Equipment Corp., Trans World Airlines, Inc., Praegitzer Industries, Inc., TWA Corp., Suvanza, Raven Acquisition Corp., Global Compliance Services, Inc., NAVEX Global, Inc., Rocketplane Global, Inc. and Valence Surface Technologies LLC. He received his undergraduate degree from San Diego State University, an undergraduate degree from The National War College and a graduate degree from George Washington University.
Wayne P. Rothbaum Wayne P. Rothbaum founded Quogue Capital LLC. Mr. Rothbaum is President at this company. He is also on the board of Iovance Biotherapeutics, Inc. In the past he occupied the position of Executive Chairman at Acerta Pharma BV. He received a graduate degree from George Washington University and an undergraduate degree from State University of New York at Binghamton.
Michael Weiser Dr. Michael Weiser is Co-Chairman at Actin Capital LLC, Co-Founder & Co-Chairman at Actin Biomed LLC, Independent Director at Ziopharm Oncology, Inc. and Emisphere Technologies, Inc., Chairman at Chelsea Therapeutics International Ltd., and a Member at The National Medical Honor Society, Alpha Omega Alpha Honor Medical Society, American Society of Clinical Oncology, at American Society of Hematology, and Association for Research in Vision & Ophthalmology. He is on the Board of Directors at Alacrity Biosciences, Inc. Prior to co-founding Actin Biomed in December 2006, Dr. Weiser was an Executive Vice President at Paramount Acquisition Corp., a Research Director at Paramount BioSciences LLC and Paramount BioCapital, Inc., a Chairman at Ivory Capital Corp., and a President & Secretary at Seward Sciences, Inc. He also served on the board at ZIOPHARM, Inc., Manhattan Pharmaceuticals, Inc., VioQuest Pharmaceuticals, Inc., Hana Biosciences, Inc., and Paramount BioCapital Asset Management, Inc. Dr. Weiser received a BA in Psychology from the University of Vermont, an MD from New York University-School of Medicine, and a PhD in Molecular Neurobiology from Cornell University.
Ryan D. Maynard Presently, Ryan D. Maynard occupies the position of Chief Financial Officer of Blade Therapeutics, Inc. He is also on the board of Iovance Biotherapeutics, Inc. He previously occupied the position of CFO, Executive VP & Head-Investor Relations at Rigel Pharmaceuticals, Inc., Controller of General Magic, Inc., Controller, Director-Finance & Accounting at Personify, Inc. (California) and Senior Finance Manager at Siliconix, Inc. Ryan D. Maynard received an undergraduate degree from Santa Clara University.
Jay Venkatesan
Iain D. Dukes Dr. Iain D. Dukes is Venture Partner at OrbiMed Advisors Private Equity. He is on the Board of Directors at Lion Biotechnologies, Inc. Dr. Dukes was previously employed as VP-External Research & Development by Amgen, Inc., President & Chief Executive Officer by Essentialis, Inc., a Principal by Glaxo Wellcome, Inc., a Principal by Glaxo, Inc., a Principal by GlaxoSmithKline, Inc., Senior VP-Business Development & Licensing by Merck & Co., Inc., and Senior Vice President by Merck Research Laboratories. He received his undergraduate degree from the University of Bath, an undergraduate degree from the University of Oxford, a graduate degree from the University of Leeds and a doctorate degree from the University of Oxford.
Merrill A. McPeak Mr. Merrill A. McPeak is an Independent Director at Iovance Biotherapeutics, Inc., an Independent Director at Research Solutions, Inc., a President at McPeak & Associates and a Member at Council on Foreign Relations, Inc. He is on the Board of Directors at Iovance Biotherapeutics, Inc., Research Solutions, Inc., FoundationWorks, Inc. and Saab Sensis Corp. Mr. McPeak was previously employed as an Independent Director by Lilis Energy, Inc., an Independent Director by Aerojet Rocketdyne Holdings, Inc., a Chairman by Mosquito Consolidated Gold Mines Ltd., a Lead Independent Director by Miller Energy Resources, Inc., a Chairman by American Battle Monuments Commission (Virginia), a Chairman by Coast Plating, Inc., a Vice Chairman by QPC Lasers, Inc., an Independent Director by DGT Holdings Corp., a Chairman by EthicsPoint, Inc., a Chairman by ECC International Corp. (Florida), a Member by United States Joint Chiefs of Staff, a Chief of Staff by United States Air Force, and a Principal by Rubicon Global Halal Advisors LLC. He also served on the board at Point Blank Solutions, Inc., Quintessence Photonics Corp., MathStar, Inc., Health Sciences Group, Inc., Gigabeam Corp., Brilliant Light Power, Inc., Western Power & Equipment Corp., Trans World Airlines, Inc., Praegitzer Industries, Inc., TWA Corp., Suvanza, Raven Acquisition Corp., Global Compliance Services, Inc., NAVEX Global, Inc., Rocketplane Global, Inc. and Valence Surface Technologies LLC. He received his undergraduate degree from San Diego State University, an undergraduate degree from The National War College and a graduate degree from George Washington University.
Athena Countouriotis Athena Countouriotis is on the board of TrovaGene, Inc., Iovance Biotherapeutics, Inc. and NuMedii, Inc. and President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. She previously occupied the position of Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc., Chief Medical Officer & Senior Vice President of Halozyme Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp. and Chief Medical Officer of Ambit Biosciences Corp. She received a doctorate from Tufts University School of Medicine and an undergraduate degree from the University of California, Los Angeles.
Maria Fardis Presently, Maria Fardis occupies the position of President, Chief Executive Officer & Director at Iovance Biotherapeutics, Inc. In her past career she was Associate Director-Project & Portfolio Management at Gilead Sciences, Inc., Chief Operating Officer of Acerta Pharma BV and Chief Oncology Operations & Alliances at Pharmacyclics LLC. She received a doctorate from the University of California, Berkeley, an undergraduate degree from the University of Illinois and an MBA from Golden Gate University.
Iain D. Dukes Dr. Iain D. Dukes is Venture Partner at OrbiMed Advisors Private Equity. He is on the Board of Directors at Lion Biotechnologies, Inc. Dr. Dukes was previously employed as VP-External Research & Development by Amgen, Inc., President & Chief Executive Officer by Essentialis, Inc., a Principal by Glaxo Wellcome, Inc., a Principal by Glaxo, Inc., a Principal by GlaxoSmithKline, Inc., Senior VP-Business Development & Licensing by Merck & Co., Inc., and Senior Vice President by Merck Research Laboratories. He received his undergraduate degree from the University of Bath, an undergraduate degree from the University of Oxford, a graduate degree from the University of Leeds and a doctorate degree from the University of Oxford.
Frederick G. Vogt Currently, Frederick G. Vogt holds the position of General Counsel at Iovance Biotherapeutics, Inc. Dr. Vogt received an undergraduate degree from Ursinus College, a doctorate from The Pennsylvania State University and a doctorate from Temple University (Pennsylvania).
Richard Gaeto Richard Gaeto is Senior Vice President-Technical Operations at Iovance Biotherapeutics, Inc.
Richard Gaeto Richard Gaeto is Senior Vice President-Technical Operations at Iovance Biotherapeutics, Inc.
Friedrich Graf Finckenstein Dr. Friedrich G. Finckenstein, MD, is a Chief Medical Officer at Iovance Biotherapeutics, Inc. He received his doctorate degree from the University of Hamburg.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐